Again
Copenhagen, DK · 2 known investors
Copenhagen-based biomanufacturing company combining AI-driven molecule discovery with in-house scale-up and production.
Also known as Again · again.bio
Investors · 2
Company profile
researched Aug 2026Again is a Copenhagen, Denmark-based company building a technology platform for the biomanufacturing industry. The platform spans three stated areas: discovery, where AI and computation are applied to identify de novo and improved molecules and production pathways using proprietary data accumulated from hundreds of thousands of hours of operation; scale-up, carried out through in-house engineering and production so that technologies are demonstrated at scale before being transferred to partners; and feedstock sovereignty, with processes designed to run on C1 waste gases or sugar rather than petrochemical inputs, drawing on academic research into alternative manufacturing feedstocks.
The company positions its output as inputs for critical manufacturing sectors, listing commodity chemicals, specialty and fine chemicals, nutraceuticals, and agrochemicals as product categories, and frames the technology as supporting re-shoring of production and supply chains. Again operates physical facilities that generate operational data, including a site referenced as TXS-1 in Texas, USA, and reports more than one trillion telemetry datapoints logged across six facilities in operation.
Business model
Again develops biomanufacturing technologies in-house and proves them at scale before transferring them to partners. Its website solicits contact from public sector bodies, licensors, co-developers, buyers/offtakers, and site partners, indicating engagement models spanning licensing, co-development, offtake, and site partnership.
Traction
Reports six facilities in operation and more than one trillion datapoints logged from telemetry.
Latest developments
The company's website references an acquisition and carries a privacy policy with an effective date of February 12, 2025.
▸Full profile — market position, technology, go-to-market, geography
Market position
Describes itself as operating a technology platform for the biomanufacturing industry, focused on producing chemicals and related products from non-petrochemical feedstocks.
Combination of AI-based molecule and pathway discovery with in-house engineering and production for scale-up, supported by proprietary operational data from its own facilities, and use of C1 waste gases or sugar feedstocks intended to decouple supply chains from oil.
Technology
The platform pairs AI and computation for discovery of de novo and improved molecules and metabolic pathways with in-house bio-engineering for scale-up, described as compressing timelines from decades to months. Processes are designed to use C1 waste gases or sugar as feedstocks instead of petrochemicals. The company operates production facilities that generate telemetry data, creating a data feedback loop for its models.
Go-to-market
Partners and customers in critical manufacturing industries, including licensors, co-developers, buyers and offtakers, site partners, and public sector organizations.
Geography
Headquartered at Emdrupvej 70, 2400 Copenhagen, Denmark, with six facilities reported in operation, including a site designated TXS-1 in Texas, USA.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
In the news
▸Research sources · 1
primary sources listed
- Againagain.bio · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Again do?
- Copenhagen-based biomanufacturing company combining AI-driven molecule discovery with in-house scale-up and production.
- Who are Again's investors?
- Again's investors include ACME Capital, DG Daiwa Ventures.
- Where is Again headquartered?
- Again is headquartered in Copenhagen, DK.